BioSpace News Archive

Noramco, LLC, a leading North American producer of controlled substance and specialty bulk Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, today announced it has reactivated its previously filed Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for the active pharmaceutical ingredient methylnaltrexone bromide.

Ligand Pharmaceuticals Incorporated announced the completion of its expected tax-free distribution of 100% of Ligand’s interest in its subsidiary OmniAb on a pro rata basis to Ligand shareholders of record as of October 26, 2022.

Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives today, reported financial results and business highlights for the third quarter ended September 30, 2022.

OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced four development programs that target fundamental pathways of cellular energetics.

Revance Therapeutics, Inc. today announced that the company will release third quarter 2022 financial results on Tuesday, November 8, 2022 after the close of market.

binx health, a healthcare technology and women’s health company focused on making routine testing broadly accessible and convenient, announced the launch of its instrument placement program for CLIA-waived facilities.

Cerus Corporation (Nasdaq:CERS) today announced it has received approval from Health Canada to extend the storage of platelets treated with the INTERCEPT Blood System from five days to seven days from the time of collection, joining other territories where INTERCEPT platelets are approved for seven-day storage.

Pardes Biosciences, Inc. announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 8:00 a.m. GMT / 12:00 a.m. PT.

Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the “Company” or “Odyssey”), announces that it has filed for United States and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device (“Nasal Device”).

Teon Therapeutics today announced that the first patient has been treated in its Phase 1/2 clinical trial evaluating the safety and efficacy of TT-816, an oral CB2 receptor antagonist acting as an immune checkpoint inhibitor while promoting T cell infiltration of cold tumors and stimulating NK cell tumor killing.